Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support

Casey Lynnette Overby, Angelika Erwin, Noura S. Abul‐Husn, Stephen B. Ellis, Stuart A. Scott, Aniwaa Owusu Obeng, Joseph Kannry, George Hripcsak, Erwin P. Böttinger, Omri GottesmanJournal of Personalized Medicine 2014 · DOI

TL;DR

This study surveyed 101 internal medicine physicians to gauge their attitudes towards adopting genome-guided prescribing via clinical decision support (CDS). While physicians generally felt comfortable with technology and saw value in genotype data for prescribing, there's a significant gap in their awareness and experience with genome-guided prescribing, highlighting a need for better education and tailored CDS design.

What Problem Does This Paper Address?

Pharmacogenomics, the study of how genes affect a person's response to drugs, holds immense promise for improving drug efficacy and reducing adverse events. However, the clinical implementation of pharmacogenomic testing has lagged behind the growing body of scientific knowledge. This lag is attributed to several factors, including insufficient physician knowledge, limited experience, and a lack of integrated tools in clinical practice. To bridge this gap, personalized medicine initiatives are developing clinical decision support (CDS) systems that can deliver genomic information at the point of care. Before widespread adoption, it's crucial to understand physicians' current attitudes, awareness, and comfort levels with these new technologies and information. This paper specifically addresses the need to assess internal medicine physicians' readiness for genome-guided prescribing through CDS, particularly before they are exposed to such systems in a pilot program.

Methods

The researchers developed a survey instrument to assess physician attitudes. This instrument was based on the Evidence-Based Practice Attitude Scale (EBPAS), adapted to measure attitudes toward adopting genome-informed interventions (EBPAS-GII). The survey also included additional questions to gauge physicians' characteristics such as awareness, experience, and perceived usefulness of decision support aids and genome-guided prescribing, as well as their attitudes towards personal genome testing (PGT) services and their comfort with technology. The survey was administered to 101 General Internal Medicine physicians at the Icahn School of Medicine at Mount Sinai (ISMMS) before they participated in a pilot pharmacogenomics project (CLIPMERGE PGx). Data analysis involved assessing internal consistency reliability of the scales, reporting frequencies of physician characteristics, and using independent t-tests and multivariable linear regressions to explore associations between predictor variables and attitudes toward genome-guided prescribing.

Datasets

The study utilized a survey administered to 101 General Internal Medicine physicians at the Icahn School of Medicine at Mount Sinai (ISMMS). No external datasets were used for training or evaluation. The survey instrument itself, adapted from the Evidence-Based Practice Attitude Scale (EBPAS), can be considered a novel data collection tool for this specific research context.

Key Insights and Ideas

  • The "Awareness Gap": While physicians are generally aware of and use standard decision support aids, there's a striking lack of awareness and experience with genome-guided prescribing. This suggests a significant disconnect between general CDS adoption and the specialized application of genomics.
  • Value Perception is Key: Physicians who believe genotype data is useful for making prescribing decisions show more positive attitudes towards adopting genome-guided CDS. This highlights that demonstrating the practical utility of genomic information is paramount for adoption.
  • Comfort with Technology, Not Yet Genomics: Physicians are largely comfortable with technology and electronic health records. This is a strong foundation, but it doesn't automatically translate to comfort with interpreting and using complex genomic information.
  • Willingness to Engage: Despite a lack of prior knowledge about PGT companies, a majority of physicians expressed willingness to use PGT services, indicating an openness to new approaches when presented.

Key Results

  • Awareness: 82.2% of physicians were aware of decision support aids, but only 37.6% were aware of genome-guided prescribing.
  • Experience: 91.0% of physicians sometimes or often use decision support aids, while only 8.9% sometimes or often use genome-guided prescribing.
  • Usefulness Perception: 81.2% found decision support aids useful for prescribing, and 53.4% found patient genotype data useful.
  • PGT Services: 59% had not heard of PGT companies, but 75% were willing to use PGT services.
  • Technology Comfort: 96.1% were comfortable or very comfortable with computers, and 78.2% with their local EHR system.
  • Predictive Factor: Physicians who perceived genotype data as useful for prescribing decisions had significantly higher attitudes toward adopting genome-guided CDS (p = 0.004), even after controlling for socially desirable responses.

Limitations and Future Work

The authors acknowledge several limitations:

  • Setting Specificity: The study was conducted at a single institution (ISMMS), which may have been early in its genomic medicine implementation. Therefore, the findings might not reflect the state of affairs at all US medical schools and healthcare institutions.
  • Focus on Internal Medicine: The study primarily focused on internal medicine trainees, who are often primary care physicians. Their views might not accurately represent physicians in other specialties or non-trainees.
  • Need for Further Validation: The study would benefit from assessing the survey instrument in other settings and conducting construct validity analyses. Convergent validity with existing EBPAS measures could also be explored.

Future work suggested includes:

  • Expanding the study to include physicians from all specialties to capture a broader range of views.
  • Analyzing how different types and years of experience shape physician views on genomic medicine.
  • Assessing the impact of the measurements from this study on the actual uptake of genome-guided CDS and physician opinions over time.
  • Prioritizing genomics education for medical students, trainees, and physicians across all disciplines, as awareness of genome-guided prescribing is currently low.

Summary updated

Abstract

This study assessed physician attitudes toward adopting genome-guided prescribing through clinical decision support (CDS), prior to enlisting in the Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics pilot pharmacogenomics project (CLIPMERGE PGx). We developed a survey instrument that includes the Evidence Based Practice Attitude Scale, adapted to measure attitudes toward adopting genome-informed interventions (EBPAS-GII). The survey also includes items to measure physicians' characteristics (awareness, experience, and perceived usefulness), attitudes about personal genome testing (PGT) services, and comfort using technology. We surveyed 101 General Internal Medicine physicians from the Icahn School of Medicine at Mount Sinai (ISMMS). The majority were residency program trainees (~88%). Prior to enlisting into CLIPMERGE PGx, most physicians were aware of and had used decision support aids. Few physicians, however, were aware of and had used genome-guided prescribing. The majority of physicians viewed decision support aids and genotype data as being useful for making prescribing decisions. Most physicians had not heard of, but were willing to use, PGT services and felt comfortable interpreting PGT results. Most physicians were comfortable with technology. Physicians who perceived genotype data to be useful in making prescribing decisions, had more positive attitudes toward adopting genome-guided prescribing through CDS. Our findings suggest that internal medicine physicians have a deficit in their familiarity and comfort interpreting and using genomic information. This has reinforced the importance of gathering feedback and guidance from our enrolled physicians when designing genome-guided CDS and the importance of prioritizing genomic medicine education at our institutions.
BibTeX
@article{overby2014physician,
  author = {Casey Lynnette Overby and Angelika Erwin and Noura S. Abul‐Husn and Stephen B. Ellis and Stuart A. Scott and Aniwaa Owusu Obeng and Joseph Kannry and George Hripcsak and Erwin P. Böttinger and Omri Gottesman},
  title = {{Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support}},
  journal = {Journal of Personalized Medicine},
  year = {2014},
  doi = {10.3390/jpm4010035},
}
Figure